SCHEMBL25314928

SCHEMBL25314928

COC(=O)c1ccc(OCCO)c(F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.47
LMNA P02545 1/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47
TTR P02766 1/20 0.47
MAPT P10636 3/20 0.46
THRA P10827 1/20 0.45
THRB P10828 1/20 0.45
CYP4A11 Q02928 3/20 0.44
CYP4F2 P78329 2/20 0.44
BCL9 O00512 1/20 0.44
CTNNB1 P35222 1/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA7 P43166 1/20 0.44
XDH P47989 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29524525 1.00 RAB9A (0.47) RAB9ALMNAMAPK1HTTTTR
SCHEMBL15295180 0.88 PDE4D (0.53) RAB9ALMNAMAPK1HTTTTR
SCHEMBL4841298 0.88 LMNA (0.47) RAB9ALMNAMAPK1HTTTTR
SCHEMBL25315062 0.88 MAPT (0.50) RAB9ALMNAMAPK1HTTTTR
Hydrochloric Acid SCHEMBL4841289 0.87 BCL9 (0.47) RAB9ALMNAMAPK1HTTTTR
SCHEMBL12365605 0.85 LMNA (0.49) RAB9ALMNAMAPK1HTTTTR
SCHEMBL14926440 0.85 THRA (0.62) RAB9ALMNAMAPK1HTTTTR
SCHEMBL6582881 0.84 KCNQ3 (0.54) RAB9ALMNAMAPK1HTTMAPT
SCHEMBL6581244 0.84 LMNA (0.50) RAB9ALMNAMAPK1HTTTTR
SCHEMBL10692700 0.84 THRA (0.64) THRATHRBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230416228-A1 AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEWYORK 2023-12-28 US disclosed
EP-4217355-A1 AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 Forkhead Biotherapeutics, inc. (US) 2023-08-02 EP disclosed
WO-2022066938-A1 AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 FORKHEAD BIOTHERAPEUTICS, INC. (US) 2022-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416228-A1 AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 FOXO1, FOXO3, GCKR RAB9A 1754/4885LMNA 3819/4885MAPK1 1867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.